OncTalk 2022
GRACE
Dual Immune Checkpoint Blockade With or Without Chemotherapy for mNSCLC
FEATURING
Chul Kim
- 278 views
- March 20, 2023
- 1
GRACE
Overcoming Resistance in ALK+ or KRAS+ NSCLC
FEATURING
Aakash Desai
- 106 views
- January 31, 2023
GRACE
NSCLC Trials for Patients With Actionable Mutations and the Importance of Quality of Life
- 143 views
- January 31, 2023
- 1
CancerGRACE
Factors for Positive Outcomes in Consolidative Therapies for NSCLC
- 42 views
- January 31, 2023
GRACE
The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies
FEATURING
Julia Rotow
- 1,541 views
- January 26, 2023
- 6
CancerGRACE
Studies in Oligometastatic NSCLC: Current Data and Definitions
FEATURING
Puneeth Iyengar
- 78 views
- January 19, 2023
GRACE
What Factors Determine a Successful Clinical Trial for NSCLC?
FEATURING
Puneeth Iyengar
- 27 views
- January 19, 2023
GRACE
Local Consolidative Therapy for Oligometastatic NSCLC: Ready for Primetime?
FEATURING
Puneeth Iyengar
- 125 views
- January 11, 2023
- 6
GRACE
Therapeutic Options in Driver-Mutation Positive mNSCLC Refractory to Frontline Small Molecular Inhibition
FEATURING
Aakash Desai
- 142 views
- January 11, 2023
- 1
GRACE
Frontline Treatment of Advanced NSCLC Without Actionable Driver Mutation
FEATURING
Chul Kim
- 188 views
- January 11, 2023
- 2